Trial Profile
A Phase I Escalating Dose Ranging Study to Evaluate the Safety and Immunogenicity of the VAX128 A, B, and C Novel H1N1 Influenza Vaccine Constructs in Healthy Adults 18-49 Years of Age and in Community Living Adults greater than or equal to 65 Years of Age.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Aug 2012
Price :
$35
*
At a glance
- Drugs VAX 128 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions
- 03 Mar 2011 Status changed from recruiting to completed.
- 14 Aug 2010 New trial record